Impact of the spheroid model complexity on drug response.

Pharmaceutical investigators are searching for preclinical models closely resembling the original cancer and predicting clinical outcome. This study compares drug response of three in vitro 3D-drug screening models with different complexity. Tumor cell line spheroids were generated from the cell lines Caco-2, DLD-1, COLO 205, HT-29 and HCT-116, and treated with clinically relevant combination therapies, namely 5-FU/oxaliplatin (FO), 5-FU/irinotecan (FI) and the molecular drugs Cetuximab, Trastuzumab, Vorinostat and Everolimus. Treatment results were compared with spheroids originated from tumor cell lines (Caco-2, DLD-1) co-cultured with stromal cells (PBMCs, cancer-associated fibroblasts of colorectal origin) and spheroids directly prepared from colon cancer tissues. Different microenvironment compositions altered the tumor cell line spheroid response patterns. Adding PBMCs increased resistance to FO treatment by 10-15% in Caco-2 and DLD-1 spheroids but decreased resistance to FI by 16% in DLD-1 spheroids. Fibroblast co-cultures decreased resistance to FI in Caco-2 spheroids by 38% but had no impact on FO. Treatment of colon cancer tissue spheroids revealed three distinct response pattern subgroups not detectable in 3D cell lines models. The cancer tissue spheroid model mimics both tumor characteristics and the stromal microenvironment and therefore is an invaluable screening model for pharmaceutical drug development.

[1]  E. Tartour,et al.  Colorectal cancer and immunity: what we know and perspectives. , 2014, World journal of gastroenterology.

[2]  A. Russo,et al.  The role of targeted therapy for gastrointestinal tumors , 2014, Expert review of gastroenterology & hepatology.

[3]  Florian Klemm,et al.  Microenvironmental regulation of therapeutic response in cancer. , 2015, Trends in cell biology.

[4]  J. Bouchal,et al.  The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance , 2014, Cancer Cell International.

[5]  F. Wong,et al.  Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen‐reactive T cell responses: position statement of the T‐Cell Workshop Committee of the Immunology of Diabetes Society , 2011, Clinical and experimental immunology.

[6]  G. Kouraklis,et al.  Histone deacetylase inhibitors and colorectal cancer: what is new? , 2014, Anti-cancer agents in medicinal chemistry.

[7]  M. Postow,et al.  Checkpoint blocking antibodies in cancer immunotherapy , 2014, FEBS letters.

[8]  Feng Gao,et al.  Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway , 2015, Medical Oncology.

[9]  M. Molloy,et al.  From mice to men: GEMMs as trial patients for new NSCLC therapies. , 2014, Seminars in cell & developmental biology.

[10]  G. Moore,et al.  Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. , 1978, Cancer research.

[11]  D. Agus,et al.  Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs , 2010, Molecular Cancer Research.

[12]  C. Culmsee,et al.  Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. , 2007, Journal of proteome research.

[13]  Y. Shaked,et al.  Host effects contributing to cancer therapy resistance. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  P. Hérait,et al.  Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Y. Yen,et al.  Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status , 2014, Molecular Cancer.

[16]  Mallika Singh,et al.  Mouse tumour models to guide drug development and identify resistance mechanisms , 2014, The Journal of pathology.

[17]  M. Brattain,et al.  Heterogeneity of malignant cells from a human colonic carcinoma. , 1981, Cancer research.

[18]  S. Nicosia,et al.  One mouse, one patient paradigm: New avatars of personalized cancer therapy. , 2014, Cancer letters.

[19]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Provencio,et al.  Cancer‐associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients , 2013, Cancer science.

[21]  Tuan-jie Li,et al.  Cancer-associated fibroblasts in digestive tumors. , 2014, World journal of gastroenterology.

[22]  N. Itano,et al.  Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.

[23]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[24]  M. Hidalgo,et al.  Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors , 2006, Clinical Cancer Research.

[25]  S. Ramalingam,et al.  Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies , 2007, Clinical Cancer Research.

[26]  J. Haycock,et al.  State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. , 2008 .

[27]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[28]  Vicky M. Avery,et al.  Advanced Cell Culture Techniques for Cancer Drug Discovery , 2014, Biology.

[29]  A. G. de Herreros,et al.  Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature , 2013, Clinical Cancer Research.

[30]  D. Richel,et al.  Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies , 2011, Investigational New Drugs.

[31]  Andreas Krieg,et al.  Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines , 2013, PloS one.

[32]  W. Scheithauer,et al.  Raltitrexed und Oxaliplatin beim kolorektalen Karzinom: In‐vitro‐ und In‐vivo‐Untersuchungen einer synergistisch wirksamen Zytostatikakombination , 2002 .

[33]  V. Grünwald,et al.  [Pharmacotherapy of solid tumors. New hopes and frustrations]. , 2014, Der Internist.

[34]  R. Kerbel,et al.  Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. , 2001, Gastroenterology.

[35]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[37]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[39]  D. Dexter,et al.  N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. , 1979, Cancer research.

[40]  G. Parham,et al.  Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer , 2001, Gynecologic and Obstetric Investigation.

[41]  Xian Xu,et al.  Three-dimensional in vitro tumor models for cancer research and drug evaluation. , 2014, Biotechnology advances.

[42]  Jinsong Liu,et al.  Tumor stroma as targets for cancer therapy. , 2013, Pharmacology & therapeutics.

[43]  Joseph M. Negri,et al.  The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.

[44]  E. Van Cutsem,et al.  Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  R. Montironi,et al.  Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma , 2013, Cancer Immunology, Immunotherapy.

[46]  L. Vermeulen,et al.  Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. , 2015, Cancer research.

[47]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[48]  L. Howells,et al.  The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention? , 2016, International journal of cancer.

[49]  Shuichi Fujimoto,et al.  Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis. , 2007, Biological & pharmaceutical bulletin.

[50]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[51]  M. Wiese,et al.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Mina J Bissell,et al.  The tumor microenvironment is a dominant force in multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[53]  W. Fang,et al.  Priming cancer cells for drug resistance: role of the fibroblast niche , 2014, Frontiers in Biology.